Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Endo Launches First US Rival To Merz’s Cuvposa

Company’s Par Unit Starts Shipping Glycopyrrolate Oral Solution

Executive Summary

Endo’s Par Pharmaceutical has begun shipping the first generic version of Merz’s Cuvposa (glycopyrrolate) 1mg/5ml oral solution in the US following FDA approval.

You may also be interested in...



Endo Counts On Vasostrict Revenues Despite Competition

Endo still sees significant potential in Vasostrict despite the onset of competition. Meanwhile, the firm says it is focusing on “optimizing” its generics business.

ANI Delivers On Cortrophin Gel US Launch

ANI Pharmaceuticals has finally delivered its long-awaited launch of purified Cortrophin Gel (repository corticotropin injection) in the US, accompanying the launch with its ‘Cortrophin In Your Corner’ dedicated program to increase access and provide reimbursement support.

IGBA Welcomes Regional Association From Balkans

To extend its representation in Europe, IGBA has welcomed the generic and biosimilar drug association of Serbia and Montenegro – Genezis – to the global off-patent industry body.

Topics

Related Companies

UsernamePublicRestriction

Register

GB151546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel